Cell and Gene Therapy Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Cell and Gene Therapy Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Cell therapy is the administration of living cells in patients for the treatment of a disease. The source of cell can be autologous or allogeneic, which can be derived from stem cells such as bone marrow. Stem cells therapy is used in bone marrow transplantation. Gene therapy is the introduction, removal, or change in the patient's genetic code for treatment of a disease. Moreover, it modifies the expression of an individual’s genes or repair abnormal genes. The therapy involves administration of nucleic acid (DNA/RNA) with carriers called as vectors.
Market Dynamics
Increasing prevalence of cancer diseases is a major factor driving the cell and gene therapy market growth. According to the World Cancer Research Funds and the American Institute for Cancer Research, in 2018, there were around 18 million cases of cancer, of which around 9.5 million were in men and around 8.5 million in women, globally. Moreover, introduction of innovative products and rich pipeline of cell and gene therapy is expected to boost the market growth. For instance, around 150 gene therapies are currently in the development stage. Gene replacement accounts for around two third of gene therapy pipeline. However, around 49% of gene therapies are under preclinical and discovery stages. During 2012-18, around 351 gene therapy deals were signed. For instance Gilead’s Kite Pharma received exclusive rights to Sangamo Therapeutics’ zinc finger nuclease gene editing technology, for $3.2bn.
Key features of the study:
This report provides in-depth analysis of the cell and gene therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cell and gene therapy market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the cell and gene therapy market
Detailed Segmentation:
Global Cell and Gene Therapy Market, By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
Global Cell and Gene Therapy Market, By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
Global Cell and Gene Therapy Market, By Scale of Operation:
In House
Outsourced
Global Cell and Gene Therapy Market, By Geography:
North America
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
U.S.
Canada
Latin America
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
GCC
Israel
Rest of Middle East
Africa
By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
By Scale of Operation:
In House
Outsourced
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Amgen *
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Biogen
BioMarin Pharmaceuticals
Bristol-Myers Squibb Company
GlaxoSmithKline
Novartis
Pfizer
Regeneron Pharmaceuticals and Sanofi
Spark Therapeutics
Agilis Biotherapeutics
Angionetics AVROBIO
Freeline Therapeutics
Horama
MeiraGTx
Myonexus Therapeutics
Nightstar Therapeutics
Kolon TissueGene, Inc.
JCR Pharmaceuticals Co., Ltd.
MEDIPOST
“*” marked represents similar segmentation in other categories in the respective section.